Company intelligence / Profile preview

Innoviva Specialty Therapeutics

Waltham, Massachusetts, United Statesinnovivaspecialtytherapeutics.com ↗

Ownership: Private
Employees: ~121
Development stage: Other

Overview

Innoviva Specialty Therapeutics commercializes four FDA-approved products in critical care and infectious disease (GIAPREZA, XERAVA, XACDURO, ZEVTERA) and leads a late-stage, pivotal program (zoliflodacin, completed Phase 3) for uncomplicated gonorrhea. Multiple programs target antimicrobial-resistant pathogens, including those with limited current treatment options.

Therapeutic areas: Infectious DiseasesCardiovascular
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

zoliflodacin

Approved

Partnerships

GlaxoSmithKline (GSK)Global Antibiotic Research & Development Partnership (GARDP)

Beyond the preview

Go deeper on Innoviva Specialty Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoviva Specialty Therapeutics.